Profile data is unavailable for this security.
About the company
Xintela AB (Xintela) is a Sweden-based biomedical company engaged in the fields of regenerative medicine and cancer, with particular focus on cartilage damage and brain tumors. In the field of regenerative medicine, the Company focuses on cartilage damage and osteoarthritis, and in the field of brain tumors, its focuses on the development of a treatment for glioblastoma, an aggressive tumor. The Company has developed therapeutic antibodies, which bind to cancer cells. It has also developed XINMARK, a marker technology which consists of specific proteins, which work as recognition flags on the surface of certain cells. The markers make it possible to identify and select certain types of stem cells which can develop into cartilage cells.
- Revenue in SEK (TTM)4.06m
- Net income in SEK-38.62m
- Incorporated2009
- Employees13.00
- LocationXintela ABScheeletorget 1LUND 223 81SwedenSWE
- Phone+46 462756500
- Websitehttps://www.xintela.se/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alzinova AB | 99.00k | -21.27m | 170.46m | 5.00 | -- | 1.23 | -- | 1,721.87 | -0.2707 | -0.2707 | 0.0012 | 1.32 | 0.0008 | -- | 0.1547 | 19,800.00 | -17.38 | -12.21 | -18.61 | -12.85 | -9,586.87 | -- | -21,481.82 | -21,390.81 | -- | -575.22 | 0.0067 | -- | -88.89 | -- | -24.71 | -- | 19.48 | -- |
| Kancera AB | 0.00 | -44.53m | 176.93m | 5.00 | -- | 3.58 | -- | -- | -0.3675 | -0.3675 | 0.00 | 0.4074 | 0.00 | -- | -- | 0.00 | -49.50 | -54.11 | -62.16 | -63.47 | -- | 70.00 | -- | -275,694.40 | -- | -- | 0.00 | -- | -- | -- | 31.32 | -- | -- | -- |
| Exact Therapeutics AS | 0.00 | -49.69m | 178.99m | 12.00 | -- | 1.63 | -- | -- | -1.53 | -1.53 | 0.00 | 1.83 | 0.00 | -- | -- | 0.00 | -48.79 | -43.50 | -64.83 | -50.76 | -- | -- | -- | -- | -- | -- | 0.0056 | -- | -- | -- | -8.27 | -- | 1.47 | -- |
| Alligator Bioscience AB | 43.21m | -131.96m | 191.77m | 15.00 | -- | -- | -- | 4.44 | -95.09 | -95.09 | 4.39 | -0.9979 | 0.4179 | -- | 9,602.67 | 960,266.70 | -127.63 | -97.96 | -- | -155.50 | -- | -- | -305.39 | -569.04 | -- | -- | 8.21 | -- | -0.5851 | 67.68 | 5.91 | -- | -- | -- |
| Annexin Pharmaceuticals AB (publ) | 0.00 | -45.77m | 193.42m | 4.00 | -- | 4.23 | -- | -- | -10.08 | -10.08 | 0.00 | 6.48 | 0.00 | -- | -- | 0.00 | -153.01 | -145.61 | -185.94 | -179.48 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.07 | -- | -- | -- |
| SoftOx Solutions AS | 8.84m | -18.65m | 220.16m | 5.00 | -- | 1.95 | -- | 24.89 | -0.014 | -0.014 | 0.0055 | 0.0532 | 0.087 | -- | 19.49 | 1,862,998.00 | -18.36 | -50.91 | -30.04 | -67.07 | -- | -- | -210.90 | -644.92 | 1.26 | -4.29 | 0.126 | -- | 13.38 | 14.06 | -8.86 | -- | -- | -- |
| Medivir AB | 3.58m | -110.52m | 226.58m | 10.00 | -- | 2.21 | -- | 63.22 | -0.9658 | -0.9658 | 0.0313 | 0.9148 | 0.0175 | -- | 0.8239 | 358,400.00 | -53.86 | -31.75 | -66.42 | -38.14 | -- | -- | -3,083.62 | -740.12 | -- | -- | 0.0723 | -- | -54.36 | -16.77 | -38.06 | -- | -- | -- |
| Initiator Pharma A/S | 0.00 | -17.20m | 250.66m | 2.00 | -- | 11.33 | -- | -- | -0.3085 | -0.3085 | 0.00 | 0.3241 | 0.00 | -- | -- | 0.00 | -61.04 | -67.58 | -63.98 | -73.43 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 53.32 | -- | -- | -- |
| Xintela AB | 4.06m | -38.62m | 256.33m | 13.00 | -- | -- | -- | 63.20 | -0.067 | -0.067 | 0.007 | -0.025 | 0.2313 | -- | 46.35 | 312,000.00 | -220.20 | -193.28 | -- | -641.86 | 100.00 | -- | -952.17 | -6,272.93 | -- | -18.59 | -- | -- | 5,303.85 | 156.45 | 27.54 | -- | -- | -- |
| Zelluna ASA | 0.00 | -196.21m | 263.18m | 27.00 | -- | 2.16 | -- | -- | -55.48 | -55.48 | 0.00 | 6.28 | 0.00 | -- | -- | 0.00 | -86.63 | -36.03 | -103.49 | -39.51 | -- | -- | -- | -- | -- | -- | 0.0118 | -- | -- | -- | -6.25 | -- | -37.05 | -- |
| Active Biotech AB publ | 0.00 | -39.90m | 273.10m | 6.00 | -- | 12.59 | -- | -- | -0.1022 | -0.1022 | 0.00 | 0.0176 | 0.00 | -- | -- | 0.00 | -119.46 | -94.38 | -174.61 | -120.44 | -- | -- | -- | -3,355.24 | -- | -- | 0.0483 | -- | -- | -- | 13.98 | -- | -- | -- |
| Cantargia AB | 0.00 | -171.62m | 281.93m | 22.00 | -- | 4.04 | -- | -- | -0.8676 | -0.8676 | 0.00 | 0.2807 | 0.00 | -- | -- | 0.00 | -118.42 | -56.56 | -169.12 | -63.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.27 | -- | -- | -- |
| AlzeCure Pharma AB | 0.00 | -35.54m | 317.86m | 11.00 | -- | 16.65 | -- | -- | -0.4072 | -0.4072 | 0.00 | 0.173 | 0.00 | -- | -- | 0.00 | -149.93 | -73.70 | -236.55 | -83.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.20 | -- | -38.94 | -- |
| Promimic AB | 44.10m | -13.53m | 326.84m | 18.00 | -- | 5.03 | -- | 7.41 | -0.7157 | -0.7157 | 2.34 | 3.44 | 0.5323 | -6.59 | 3.65 | 2,320,842.00 | -16.33 | -20.50 | -19.59 | -24.44 | 109.57 | 104.49 | -30.69 | -59.75 | 3.48 | -- | 0.00 | -- | 18.63 | 50.25 | -36.09 | -- | -- | -- |
| Curasight A/S | -45.16m | -51.17m | 332.01m | 4.00 | -- | 34.96 | -- | -- | -0.9116 | -0.9116 | -0.8077 | 0.0681 | -1.33 | -- | -- | -7,511,250.00 | -150.54 | -37.34 | -262.94 | -40.89 | -- | -- | -- | -- | -- | -15.84 | 0.8178 | -- | -27.21 | -- | -40.76 | -- | -- | -- |
| Intervacc AB | 13.97m | -71.30m | 333.66m | 15.00 | -- | 0.974 | -- | 23.89 | -0.7373 | -0.7373 | 0.1294 | 1.01 | 0.0464 | 1.53 | 2.46 | 931,133.30 | -23.68 | -20.93 | -25.31 | -22.44 | -11.06 | -7.76 | -510.47 | -753.03 | 10.68 | -- | 0.00 | -- | 47.06 | -0.5868 | 26.58 | -- | -52.41 | -- |
Data as of Jul 15 2025. Currency figures normalised to Xintela AB's reporting currency: Swedish Krona SEK
0.02%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| FCG Fonder ABas of 31 Mar 2025 | 110.09k | 0.02% |
Data from 30 May 2025 - 30 May 2025Source: FactSet Research Systems Inc.
